Oral nirmatrelvir-ritonavir for COVID-19 in higher risk outpatients
Richards et al., New England Journal of Medicine, CanTreatCOVID, Sep 2025
Abstract for hidden CanTreatCOVID results showing the hospitalization/death results only.
Standard of Care (SOC) for COVID-19 in the study country,
the United Kingdom, is
very poor with
very low average efficacy for approved treatments
1.
The United Kingdom focused on expensive high-profit treatments, approving only one low-cost early treatment, which required a prescription and had limited adoption. The high-cost prescription treatment strategy reduces the probability of early treatment due to access and cost barriers, and eliminates complementary and synergistic benefits seen with many low-cost treatments.
|
risk of death/hospitalization, 51.7% lower, RR 0.48, p = 0.39, treatment 2 of 343 (0.6%), control 4 of 324 (1.2%), NNT 153, odds ratio converted to relative risk, day 28.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Richards et al., 12 Sep 2025, Randomized Controlled Trial, United Kingdom, peer-reviewed, 1 author, study period 8 December, 2021 - 30 September, 2024, CanTreatCOVID trial.
